XRAY
Undervalued by 162.7% based on the discounted cash flow analysis.
Market cap | $2.81 Billion |
---|---|
Enterprise Value | $4.81 Billion |
Dividend Yield | $0.64 (4.545454545454549%) |
Earnings per Share | $-4.48 |
Beta | 0.93 |
Outstanding Shares | 198,800,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -3.08 |
---|---|
PEG | 0.41 |
Price to Sales | 0.83 |
Price to Book Ratio | 1.76 |
Enterprise Value to Revenue | 1.27 |
Enterprise Value to EBIT | -14.92 |
Enterprise Value to Net Income | -6 |
Total Debt to Enterprise | 0.47 |
Debt to Equity | 1.17 |
No data
No data